Given that hematologic toxicities are the most common dose-limiting events, routine complete blood count monitoring is recommended at baseline and at least weekly during treatment and prophylactic granulocyte colony-stimulating factor (G-CSF) is advised for patients at high risk of neutropenia. The gene discussed is CSF3; the disease is neutropenia.